Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Moderate to severe vasomotor symptoms due to menopause (estradiol component, off-label for testosterone),Male hypogonadism (testosterone component)
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Testosterone cypionate: Hydrolyzed to testosterone then metabolized primarily in the liver via oxidation (CYP3A4, CYP2C9) and conjugation; estradiol cypionate: Hydrolyzed to estradiol then metabolized via hydroxylation (CYP1A2, CYP3A4) and glucuronidation.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Testosterone: 97-99% bound to sex hormone-binding globulin (SHBG) and albumin; estradiol: 98% bound to SHBG and albumin.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
Testosterone: approximately 0.6 L/kg; estradiol: approximately 0.5 L/kg. Indicates distribution into peripheral tissues.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Intramuscular: approximately 100% due to slow release from oil depot; no oral bioavailability (hepatic first-pass inactivation).
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
No specific dose adjustment recommended; use with caution in severe impairment due to limited data.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use with caution and monitor hepatic function.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Use lower end of dosing range (e.g., testosterone cypionate 50-100 mg with estradiol cypionate 2-5 mg every 4 weeks) due to increased risk of cardiovascular and prostate adverse effects; monitor closely.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
Estrogens, with or without progestins, should not be used for the prevention of cardiovascular disease or dementia. Increased risks of endometrial cancer, stroke, and deep vein thrombosis. Venous thromboembolism risk is increased with estrogen-containing products.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Cardiovascular risk: increased risk of myocardial infarction, stroke, venous thromboembolism,Endometrial cancer: unopposed estrogen use increases risk,Breast cancer: caution in patients with known or suspected estrogen-dependent tumors,Hepatic impairment: dose adjustment may be needed,Hypercalcemia: caution in patients with bone metastases,Fluid retention: caution in cardiac or renal dysfunction
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Pregnancy (estrogen component),Breast cancer (known, suspected, or history, unless appropriate indication),Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Active thromboembolic disease or history of thromboembolism (e.g., DVT, PE),Known hypersensitivity to components,Men with prostate or breast cancer (testosterone component)
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Avoid excessive grapefruit juice as it may affect hormone metabolism. No specific food interactions; maintain a balanced diet.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalities. Third trimester: Possible advanced bone age and growth acceleration. Not recommended in any trimester.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Contraindicated during breast-feeding. Excreted in breast milk, may cause masculinization of female infant. M/P ratio not known.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
Not recommended for use during pregnancy; dose adjustment is not applicable.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
Monitor for signs of thromboembolism, especially in patients with risk factors. Measure serum testosterone and estradiol levels periodically to maintain therapeutic range. Use with caution in patients with history of myocardial infarction or stroke. Contraindicated in men with breast or prostate cancer. May cause gynecomastia and fluid retention.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Report any signs of blood clots (leg pain, chest pain, shortness of breath) immediately.,Do not use if you are pregnant or breastfeeding.,Regular blood tests are required to monitor hormone levels and liver function.,Use as prescribed; do not adjust dose without consulting your healthcare provider.,Inform your doctor about all medications you are taking, including over-the-counter drugs.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
"Estradiol (estrogen) may reduce the anticoagulant effect of warfarin, likely by enhancing the synthesis of clotting factors (e.g., factors II, VII, IX, X) in the liver. This interaction can lead to a decrease in the International Normalized Ratio (INR) and potentially increase the risk of thromboembolic events. Conversely, when estradiol is discontinued, warfarin's effect may increase, raising the risk of bleeding."
"Acitretin, a retinoid used for psoriasis, induces CYP3A4 enzymes, accelerating estradiol metabolism and reducing its systemic exposure. This can lead to decreased contraceptive efficacy of estrogen-containing oral contraceptives, potentially resulting in unplanned pregnancy. Additionally, acitretin itself is teratogenic, making effective contraception critical during therapy."
"The combination of Halcinonide, a potent topical corticosteroid, with Estradiol may lead to increased systemic absorption of Estradiol due to corticosteroid-induced inhibition of estrogen metabolism via competition for cytochrome P450 enzymes, particularly CYP3A4. This interaction can result in elevated estradiol serum concentrations, potentially augmenting estrogenic effects such as thromboembolic risk, endometrial hyperplasia, and hormonal imbalance. Clinically, patients may experience symptoms like breakthrough bleeding, breast tenderness, or worsened side effects of estrogen therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE vs ANDROID 5, answered by our medical review team.
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is a Androgen that works by Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE and ANDROID 5 depend on the specific clinical indication. These are both Androgen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is: Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is classified as Category D/X. First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalitie. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.